DOI : 10.1055/s-00000059

Pneumologie

Issue S 01 · Volume 69 · March 2015 DOI: 10.1055/s-005-28563

56. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.

Berlin, 18.–21. 3. 2015
Kongresspräsident: Prof. Dr. med. Torsten T. Bauer, Berlin


V54
Schuler, M; Planchard, D; Yang, JC; De Marinis, F; Bennouna, J; Kim, JH; Chouaid, C; Wiewrodt, R; Grossi, F; Feng, J; Strausz, J; Lu, S; Kim, DW; Liu, X; Chen, YM; Zhou, C; Wang, B; Chand, VK; Park, K: Continuation of afatinib (A) beyond progression: results of a randomized, open-label, phase III trial of A plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small-cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and A: LUX-Lung 5 (LL5)
V133
Griesinger, F; Lüers, A; Prenzel, R; Douglas, S; Willborn, KC; Stropiep, U; Falk, M; Hallas, C; Tiemann, M: Incidence and treatment outcome of EGFR and inactivating P53 alterations in a cohort of 218 consecutively tested patients from a certified lung cancer center
V152
Pawel, J von; Tseng, J; Dediu, M; Schumann, C; Moritz, B; Mendell, J; Jin, X; Feng, W; Copigneaux, C; Beckman, RA: Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs)
V192
Kreuter, M; Vansteenkiste, J; Fischer, J; Eberhardt, W; Zabeck, H; Kollmeier, J; Serke, M; Frickhofen, N; Reck, M; Engel-Riedel, W; Neumann, S; Thomer, M; Schuhmann, C; De Leyn, P; Graeter, T; Stamatis, G; Griesinger, F; Thomas, M: Langzeit Ergebnisse der randomisierten Phase 2 Studie zur Verbesserung der adjuvanten Chemotherapie beim frühen NSCLC – Vergleich Cisplatin/Pemetrexed (CPx) mit Cisplatin/Vinorelbine (CVb) (TREAT)